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Abstract: In this narrative review, we summarize recent pieces of evidence of the role of microbiota
alterations in Rett syndrome (RTT). Neurological problems are prominent features of the syndrome,
but the pathogenic mechanisms modulating its severity are still poorly understood. Gut microbiota
was recently demonstrated to be altered both in animal models and humans with different
neurodevelopmental disorders and/or epilepsy. By investigating gut microbiota in RTT cohorts, a less
rich microbial community was identified which was associated with alterations of fecal microbial
short-chain fatty acids. These changes were positively correlated with severe clinical outcomes.
Indeed, microbial metabolites can play a crucial role both locally and systemically, having dynamic
effects on host metabolism and gene expression in many organs. Similar alterations were found in
patients with autism and down syndrome as well, suggesting a potential common pathway of gut
microbiota involvement in neurodevelopmental disorders.
Keywords: neurodevelopment; Rett syndrome; autism spectrum disorder; gut microbiota; Clostridium;
Sutterella
1. Introduction
The commensal microbial community inhabiting the mammalian gastrointestinal tract, microbiota,
has been demonstrated to exert important functions both prenatally and postnatally [1]. Several studies
on germ-free mice established that, at the local level, the presence of pioneering microorganisms
triggers the correct development and maturation of the gut-associated lymphoid tissue. Indeed,
in the absence of microbiota, animals fail to complete Peyer patches and mesenteric lymph nodes
maturation and display longer and thinner villi with a reduced vascular network [2]. This intuitive
and intimate relationship between the gut and its microbiota during development also applies to
distant districts, with the brain as the most counterintuitive and intriguing. Microbial-derived signals
are crucial for the physiological brain development, promoting neurotrophins secretion [3], microglia
maturation [4], blood-brain barrier functionality (by enhancing tight-junction expression) [5], and
correct myelination [6]. Brain development is tremendously vulnerable to environmental factors, and
events occurring in early phases might have long-term effects later in life [7]. Beside the described
role in early infancy, the microbiota-gut-brain axis was recently recognized to be a highly complex
and tightly regulated bidirectional network. From top to bottom, it encompasses the central nervous
system (CNS), the sympathetic and parasympathetic branches of the autonomic nervous system, the
enteric nervous system, and the neuroendocrine and neuroimmune systems [8]. This complex network
is enriched by the gut microbial community exerting a bottom-up modulation by interacting mainly
with the vagus nerve and the neuroendocrine and neuroimmune systems [9].
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In this review, we will focus on gut microbiota changes in Rett syndrome (RTT), the most prevalent
neurodevelopmental disorder in females, whose pathogenic mechanisms are still poorly understood
and whose genetic background cannot fully explain the phenotypic heterogeneity.
2. Gut Microbiome Alterations in Neurodevelopmental Disorders
Neurodevelopmental disorders (NDs) are chronic disorders that affect CNS function during the
developmental period in the domains of motor skills, cognition, communication, and/or behavior.
The diagnosis of NDs is primarily clinical, based on a constellation of behaviors/symptoms that are
specified in the diagnostic and statistical manual of mental disorders (DSM) [10]. The most common
ND worldwide is autism spectrum disorder (ASD), for which several studies, conducted since 2000
in different geographical regions and by different teams, have estimated a median prevalence of
62/10,000 [11].
ASD is an extremely heterogeneous neurodevelopmental disorder and its onset can vary. Some
children show signs from early infancy, while others exhibit symptoms of regression around 18–24
months. Other specific features may be recognizable only at an older age. Clinically, ASD is
characterized by stereotypical behaviors and a deficit in social interaction and communication [12].
In addition to the neuropsychiatric features, children with ASD often experience gastrointestinal (GI)
problems that are more frequent and more severe compared with children from the general population.
Functional constipation is the most common issue [13], followed by diarrhea/chronic diarrhea,
abdominal pain or discomfort, bloating, gas or flatulence, soiling, incontinence or bedwetting, reflux
or heartburn, nausea or vomiting, and pain or difficulties in bowel movement [14]. Gastrointestinal
symptoms strongly correlate with the severity of autism and with increased irritability, anxiety, and
social withdrawal [15,16]. This evidence elicits researches focusing on the connection between ASD
and the gut microbiota. Intriguingly, an altered composition of gut microbiome has been demonstrated
in subjects with ASD [17–20], suggesting a possible link between dysbiosis (an aberrant shift in
microbial ecology) and neurodevelopmental diseases. Despite differences in cohorts, study designs,
and methodologies, a common microbial signature has been identified (reviewed by Ding et al. [21]
and by the recent systematic review by Liu et al. [22]). ASD-related major changes involve an increase
in the relative abundance of Clostridium spp. and Sutterella spp., Bacteroides spp. and Desulfovibrio
spp. and a depletion in Bifidobacterium spp., Blautia spp., Prevotella spp., and Veillonella spp. [19,23,24].
The Clostridium hypothesis, suggesting the involvement of toxigenic bacteria in the onset of the ASD
regressive form, was first suggested by Ellen Bolte [25] and later supported by other authors [26,27].
Indeed, clostridia are spore-forming and can exert a toxic activity by producing exotoxins, phenol,
and p-cresol [27,28]. P-cresol has been postulated as a possible urinary biomarker in ASD and its
concentration correlates with constipation (slow fecal transit) [29]. Other microbial-derived metabolites
have been linked to ASD in recent years, including propionate. Propionate is a short-chain fatty
acid (SFCA) and one of the main products of microbial fermentation, together with acetate and
butyrate. SCFAs are utilized by the host as an energy source and exert other physiological functions.
SCFAs participate in glucose homeostasis, affect lipid metabolism, regulate the immune system and
inflammatory response, and serve as signaling molecules [30].
Intracerebroventricular injection of propionate in rodents was found to cause social impairment [31],
as well as behavioral, neuropathological, and biochemical changes associated with ASD [32]. However,
the contribution of microbial metabolites to ASD still must be elucidated, taking into account that fecal
SCFAs were reported to be either lower or higher in ASD children [15,33,34].
Among genetic NDs, down syndrome (OMIM #190685, trisomy 21–DS) is the most frequent cause
of intellectual disability (ID). ASD features and the high prevalence of gastrointestinal system alterations
(about 50%) often characterize DS individuals [35]. Despite DS incidence and the suggestive features of
a possible gut microbiota modulation, only one study has investigated the DS gut microbial community
thus far. Biagi and coworkers [36] compared 17 DS adults with a matched group of healthy controls.
The authors reported specific changes in the microbial community of individuals affected by DS, with
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some of them being associated with behavioral traits. Although DS gut microbiota does not significantly
differ in the relative abundance of the dominant microbial families (i.e., Ruminococcaceae, Lachnospiraceae,
Clostridiales, Bifidobacteriaceae, and Bacteroidaceae), some subdominant taxa are differently represented
in DS compared with healthy controls. In particular, the relative abundance of Parasporobacterium
spp. and Sutterella spp. is increased, whereas Veillonellaceae is reduced. Besides, when considering the
severity of neurobehavioral manifestations in DS patients, Sutterella was positively correlated with
the aberrant behavior checklist (ABC) total score, while no correlation was found between ABC and
Parasporobacterium or Veillonellaceae.
3. Gut Microbiome Alterations in Rett Syndrome
Although Rett syndrome (RTT) is no longer categorized as a pervasive developmental
disorder, patients share certain features with ASD. RTT (OMIM #312750) is an X-linked dominant
neurodevelopmental disorder and one of the most common causes of ID in females. Of all cases, 90–95%
are associated with pathogenic variants in the MECP2 (Methyl CpG Binding Protein 2) gene, encoding
a chromatin-associated protein that can both activate and repress transcription [37,38]. The RTT core
phenotype mainly consists of neurological problems (partial/complete loss of acquired purposeful
hand skills; partial/complete loss of acquired spoken language; gait abnormalities; stereotypic hand
movements) [39]. Most girls affected by RTT experience epileptic seizures, with epilepsy representing
a major concern of RTT caregivers and having a crucial impact on children and their family’s quality of
life [40]. In addition to epilepsy, parental stress is affected by their daughters’ GI pain experience [41].
Indeed, one of the major issues impacting patients affected by RTT on a daily basis is represented
by gastrointestinal and nutritional problems [42]. Families reported a series of different symptoms,
such as straining with bowel movements, the passage of hard stools, constipation, and prolonged
feeding time or chewing difficulty in more than 50% of RTT patients [42]. More recently, cholelithiasis,
or gallbladder disease, has been reported to be relatively frequent in RTT, and should be considered
one of the causes of abdominal pain [43]. Due to the high frequency of gastrointestinal comorbidities,
recommendations for managing GI symptoms have been recently developed [44].
Despite the similar features with ASD and the observation of the frequent gastrointestinal
discomfort reported by RTT caregivers, the study of possible microbial alterations characterizing RTT
gut microbiota is still relatively new. Only two Italian groups have investigated this aspect in RTT girls
thus far. The characteristics and main results of these studies are outlined in Table 1.
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Table 1. Characteristics of gut microbiota studies in Rett syndrome (RTT).
Reference Cohort Mean Age (years) Age Range GIa Symptoms (%) Methods Results (RTT vs HCb)
Strati et al., 2017
50 RTT 12.6 ± 7.3 1.5–32
68%
16S rRNA sequencing:
V3-V5 hypervariable regions;
454 pyrosequencing platform; Greengenes
Version 13.05
↓ α-diversityc
β- diversityd (p ≤ 0.003)
↑ Actinobacteria
↓ Bacteroidetes
↑ Bifidobacterium spp.
↑ Clostridium spp., Enterococcus,
Erysipelotrichaceae incertae sedis, Escherichia/Shigella
and Megasphaera
↑ Candida spp.
(MECp2; n = 48)
(CDKL5; n = 2)
29 HCb 17.4 ± 9.6 1.5–32
SCFAe quantification:
Gas chromatography
↑ Propionate, iso-butyrate and iso-valerate (in feces)
Borghi et al., 2017
8 RTT 23.0 ± 8.7 9–39
100%
16S rRNA sequencing:
V3-V4 hypervariable regions; MiSeq
Illumina platform; Greengenes
Version 13.8
↓ α-diversityc (a severity-related decrease)
β- diversityd (p ≤ 0.05, only severe RTT vs HC)
↑ Bacteroides spp.
↑ Clostridium spp.
↑ Sutterella spp.
↓ Faecalibacterium spp.
↓ Roseburia spp.
↓ Prevotella spp.
↑ Enterobacteriacae, Bacteroidaceae
and Erysipelotrichaceae (severity-related)
(MECp2; n = 8)
10 HCb 24.5 ± 6.6 18–41
SCFAe quantification:
Gas chromatography
↑ Propionate, butyrate, iso-butyrate and iso-valerate
(in feces)
aGI, Gastrointestinal tract; bHC, healthy controls; cα-diversity, the diversity in the bacterial composition within each sample; dβ- diversity, the diversity between sample groups; eSCFA,
short-chain fatty acids.
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Because of the higher vulnerability to respiratory infections related both to RTT itself and to the
different associated comorbidities (e.g. scoliosis, epilepsy, ID) [45], subjects with RTT may be exposed
to several antibiotics to prevent/cure recurrent respiratory infections. Antibiotics are responsible for
altering the gut microbiome. For this reason, in the studies conducted on RTT girls, a common exclusion
criterion was an antibiotic assumption in the three months preceding the collection of the sample.
RTT gut microbiota is characterized by a reduction in α-diversity [46,47]. α-diversity metrics
allow studying the richness, i.e., the number of unique microbial taxa within a given sample, as well
as the evenness, how uniformly the unique taxa are distributed, and the phylogenetic relatedness
between them. The loss of microbial diversity is considered a hallmark of dysbiosis, paving the way
to a reduced gut microbiota resilience [48]. Thus, the gut microbial ecosystem of RTT girls can be
considered intrinsically more susceptible to disease status. The decrease in diversity observed in RTT
patients is more pronounced in severe phenotypes, as patients with a lower diversity have higher
clinical severity scale (CSS) scores [47].
β-diversity (Unifrac distances) analyses, which measure dissimilarities in microbial community
composition between samples, showed that RTT gut microbial community clustered according to the
disease status. On the one hand, Strati and coworkers grouped RTT patients according to GI dysfunction
and observed that health status, not GI symptoms, distinguish the patients from healthy controls,
whereas constipated RTT and non-constipated RTT were not statistically different. On the other hand,
the severity of the disease further stratified RTT patients [47]. In particular, unweighted Unifrac metric,
which considers both rare and common bacterial taxa, highlighted a significant dissimilarity between
the RTT and healthy subjects, suggesting that, as described for DS [36], subdominant taxa are differently
represented. The analyses on the relative microbial abundance at different taxonomic levels showed an
enrichment in Erysipelotrichaceae in RTT patients and, at the genus level, of Clostridium spp., Sutterella
spp., and Escherichia spp. [46,47]. Other taxa were found to be discordant between the two studies,
i.e., Bifidobacterium and Bacteroides. Bifidobacteria data could suffer from an age-related abundance.
Indeed, Strati et al. enrolled younger girls affected by RTT, with a consistent number of children
younger than 10 years old. This taxon is well-known to inversely correlate with age, with the highest
abundance during lactation [49]. Like the microbial alterations reported in ASD patients, Borghi et al.
observed a decrease in Bacteroides spp. [47]. This genus, as well as Bacteroidetes, are reported to be
negatively correlated with body-mass index (BMI) [50–52]. BMI values were lower in the RTT group,
justifying this observation. Anthropometric measurements were not specified in the second cohort.
Despite differences in the observed taxa relative abundances in the two studies, a common increase
in the fecal concentration of branched-chain fatty acids (iso-butyrate and iso-valerate-BCFAs) and,
to a lesser extent, of propionate and butyrate, has been observed. BCFAs are byproducts of protein
degradation, especially of animal proteins that are rich in branched-chain amino acids, by proteolytic
bacteria such as Bacteroidetes. Dietary survey [47] showed a higher protein consumption, mainly due
to higher animal protein intake, and a lower fiber intake in RTT compared with healthy controls. No
specific dietary recommendations for RTT patients have been reported so far, but proteins might be
preferred for the increased ratio nutrients/volume, considering eating difficulties, palatability, and
texture. Beside BCFAs, proteolysis results in the production of phenolic and indolic compounds.
As already mentioned for ASD, p-cresol, the main phenolic product, is a toxic compound and has
been demonstrated to be able to alter the intestinal barrier permeability [53]. Although no study has
evaluated its fecal or urinary concentrations in RTT subjects to date, the enrichment in gut microbiota
in the main producing species, i.e., Clostridium spp. [46,47] Bacteroides spp. [47], suggests a possible
increase of p-cresol also in RTT.
Mouse models of RTT are available and they recapitulate several neurological features observed in
patients [54], including altered cortical rhythms and enhanced susceptibility to epileptic seizures [55,56].
Moreover, severe modifications in the colon organization are present in MeCP2 mutant mice [57],
suggesting that alterations occurring at the gut level, including gut microbiome, could be associated
with the classical neurological impairments observed in RTT mice. Despite this evidence, the gut
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microbiota of RTT mouse models has not been explored to date, and the aspects related to the gut
microbiome-brain axis in this murine model have not been examined.
4. Gut Microbiome Alterations in Epilepsy
Both RTT and ASD are often comorbid with seizure disorders [58]. Although it is not mentioned
in the diagnostic criteria [39], up to 70% of girls affected by RTT experience frequent seizures, and 30%
of them are resistant to the available antiepileptic drugs (AEDs) [59]. In classic RTT, the mean age of
epilepsy onset is 4 years. Seizure frequency and severity usually have an age-dependent course, as
girls aged 10–14 years are the most difficult to treat and often require AED polytherapy [60]. Recent
findings from the Rett Natural History Study pointed out that seizures in RTT may show a pattern of
remission and relapse within the lifetime. Specific MECP2 mutations are not significantly associated
with either seizure prevalence or seizure severity, although seizure prevalence is associated with
disease severity [61].
The potential role of gut microbiota in epilepsy is currently emerging. He et al. [62] studied a patient
with a 17-year history of epilepsy, which improved after fecal microbiota transplantation treatment
for Crohn’s disease. More recently, the gut microbial community in patients with drug-resistant
epilepsy was found to be significantly altered with an abnormally increased abundance of rare bacteria
mainly belonging from the phylum Firmicutes. On the contrary, the gut microbiome of patients with
drug-sensitive epilepsy was more similar to that of healthy controls. Therefore, it can be speculated that
gut dysbiosis may be involved in the pathogenesis of drug-resistant epilepsy [63]. In particular, patients
with seizures responsive to AEDs have a greater amount of bifidobacteria and lactobacilli, which could
be interpreted as protective factors for epilepsy [63]. Indeed, a recent study on drug-resistant epilepsy
showed that probiotic supplementation with a mixture of bifidobacteria and lactobacilli reduces both
seizures and sCD14 serum concentration, a recognized marker for bacterial translocation [64].
Many drugs have been demonstrated to modulate or alter the gut microbial community.
In particular, compounds targeting the nervous system exhibited a significant anticommensal activity
on a broad range of microorganisms [65]. Although the direct role of AEDs has not been investigated
to date, it is plausible, although not yet elucidated [47].
Other pieces of evidence based on diet modification support the possible role of gut microbiota
in modulating epilepsy. The ketogenic diet (KD) is a high-fat, adequate-protein, low-carbohydrate
diet used as a treatment for neurometabolic disorders, such as glucose transporter 1 (Glut1)-deficiency
syndrome, and for drug-resistant epilepsy. Considering the unbalanced macronutrient composition
of the KD, it is expected to induce some changes in gut microbiota. Tagliabue et al. [66] evaluated
the gut microbiota composition in six children with Glut1-deficiency syndrome after three months
of KD treatment and did not find statistically significant differences in Firmicutes and Bacteroidetes.
However, they found a statistically significant increase in Desulfovibrio spp., a subdominant taxon
reported in inflammatory bowel disease and other inflammatory conditions [67].
Xie and coworkers [68] found that the gut microbiota of Chinese epileptic children differed
from age-matched healthy infants and reported that the KD strongly improved gut microbiota
alterations, promoting seizure reductions. Another study, which enrolled 20 children with refractory
epilepsy, observed distinctive microbial changes in KD-responder (seizure-free or ≥ 50% of seizure
reduction) and non-responder patients (<50% of seizure reduction). The KD-responders were
characterized by an increase in the relative abundance of Bacteroidetes, whereas non-responders
showed a significant increase in the relative abundance of the Firmicutes (Clostridiales, Clostridia,
Ruminococcaceae, Lachnospiraceae, Alistipes, and Rikenellaceae) [69]. A further study on KD treatment for
severe epilepsy in Swedish children, which applied a shotgun metagenomic DNA sequencing approach,
found that alpha diversity was not significantly changed by diet. The study highlighted a decrease
in the relative abundance of Actinobacteria and Firmicutes, and an increase of Bacteroidetes and
Proteobacteria [70]. Intriguingly, microbiota changes were linked to functional changes, particularly in
relation to carbohydrates metabolism pathways.
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The KD has been investigated as a possible intervention in RTT [71], especially in the CDKL5-related
variant, which is characterized by multiple seizure-type epilepsy and a poor response to AEDs [72].
Major concerns to a broad application of the KD are the reported poor long-term efficacy and lack
of adherence.
Despite the growing number of studies on the KD and its impact on microbiota in epilepsy, the
findings should be interpreted with caution because of the small number of patients involved, the
different epilepsy etiology, and the specific diet composition. Nevertheless, the accumulating evidence
suggests the need for a better understanding of the state of dysbiosis to establish strategies to possibly
counterbalance it.
5. Discussion
Intriguingly, neurodevelopmental disorders sharing clinical features display a microbial signature
or are at least enriched/depleted in the same taxa. The major overlaps, both clinical and microbial, are
highlighted in the Venn diagram (Figure 1).
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Figure 1. Venn diagram presenting the shared clinical and microbial features between Rett Syndrome,
autism spectrum disorder, and down syndrome.
The diagram was generated (http://bioinfogp.cnb.csic.es/tools/venny/index.html) considering only
microbial changes reported in most studies (i.e., discarding discordant findings).
In particular, an enrichment in Sutterella spp. has been reported in all the reviewed NDs. A similar
trend was also observed in attention-deficit/hyperactivity disorder (ADHD) [73] and in rodent models
with Alzheimer’s disease [74] and ASD [75]. Sutterella belongs to Beta-proteobacteria, gram-negative
bacterium. Due to the reported higher relative abundance in several human diseases, Hiippala and
coworkers [76] assessed its in vitro pro-inflammatory activity and compared it with the well-known
Escherichia coli (gamma-Proteobacteria). Sutterella demonstrated only a mild pro-inflammatory activity
on intestinal epithelial cells, which was not sufficient to induce GI homeostasis alterations. On the
other hand, this taxon was demonstrated to efficiently adhere to enterocytes [77], and the effect of a
direct cross-talk with these cells in the frame of the gut-brain-axis warrants further elucidation.
Similarly, RTT and ASD subjects share an increase in the relative abundance of Clostridium spp. This
taxon, together with Bacteroides spp., is well-known for its proteolytic ability, which results in potentially
toxic compounds that can impact on gut homeostasis and permeability [53] and can affect the survival
of other beneficial microorganisms, such as lactic bacteria [77]. Bifidobacteria and lactobacilli are
known to be able to secrete neurotransmitters, particularly the gamma-aminobutyric acid (GABA) [78].
A decrease in GABA and its signaling is suggested to be involved in many ND-associated clinical
features, i.e., stereotypies, hypersensitivities, and seizures [79–81]. Moreover, the same taxa have
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been shown to promote intestinal mucosa integrity [82], decreasing local and systemic inflammatory
status. CNS is highly susceptible to inflammation, contributing to the pathogenesis of RTT [83] and to
associated comorbidities. In particular, neuroinflammation has been demonstrated to trigger seizures
in patients with epilepsy [84]. A direct role of gut microbiota in eliciting inflammation and, in turn,
seizure occurrence, has been postulated and investigated in animal models [85].
Although speculative conclusions about microbiota-dependent modifications in brain function
and behaviors have been raised over recent years (summarized in the context of NDs in Figure 2),
no studies have directly assessed the molecular or neurophysiological mechanisms responsible for
neurodevelopmental alterations characteristic of NDs [86].
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Figure 2. Microbial modulation in neurodevelopmental disorders. Effects driven directly or
indirectly by gut microbes, found to be increased in NDs and their products. (A) Clostridia are
spore-forming, toxigenic bacteria, with proteolytic ability [53]; digestion of aromatic amino acids results
in phenol, p-cresol, and indole production. High indole concentrations can suppress bifidobacteria and
lactobacilli growth [77]. Lactic bacteria are known to endogenously produce gamma-aminobutyric
acid (GABA) [78]. GABA decrease has been reported as an underlying mechanism for stereotypies
occurrence [79], ASD hypersensitivity [80], and epilepsy [81]. (B) Enterobacteriaceae [87], Sutturella
spp. [76], and Erysipelotrichaceae [88] have been reported to exert a pro-inflammatory effect, which can
alter gastrointestinal homeostasis and alter the gastrointestinal (GI) barrier permeability. (C) Bacteroides
are nutritionally versatile bacteria, with both saccharolytic and proteolytic activity [53]; a rich-protein
diet promotes the production of branched-chain fatty acids (BCFAs) and propionate [89]. High
propionate concentrations have demonstrated to exert behavioral and social impairment in animal
models [31].
Most of the literature has focused either on the clinical aspect or on the microbiome alterations.
Nevertheless, NDs are characterized by multifaceted phenotypes that might contribute to the observed
differences in the microbiota among various cohorts. A co prehensive approach, combining detailed
clinical description with microbiological data, is needed to better understand underlying relationships
betwee symptoms and specific microbial alterations.
6. Conclusions
Although microbiome studies in RTT patients are in their early stages, several authors
have investigated this aspect in ASD, which shares several clinical similarities with RTT. Main
changes in the gut microbial community suggest enrichment in pro-inflammatory species that could
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promote alterations in the gut permeability and its barrier function. Within the context of the
gut-brain axis, these microbiota-dependent modifications could trigger common behavioral and
neurodevelopmental features.
The observation of the presence of a dysbiosis in patients with NDs, especially ASD, triggers
the development of innovative therapeutic strategies throughout microbiome-based treatment.
Nevertheless, clinical trials with probiotic supplementation are currently limited and lack standardized
probiotic regimen, i.e., different administered strains or concentrations and duration of treatment.
No clinical trials have been carried out on RTT cohorts thus far.
In addition to probiotic intervention, a careful diet survey on large cohorts of RTT patients would
allow the development of diet recommendations that might mitigate microbiome alterations per se.
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